Skip to main content

Table 3 HRs for 30-day and 90-day survival according to TSH cut-off values

From: The impact of serum thyroid-stimulation hormone levels on the outcome of hepatitis B virus related acute-on-chronic liver failure: an observational study

 

30-day survival ( TSH ≥ 0.261 vs. TSH < 0.261)

90-day survival (TSH ≥ 0.261 vs. TSH < 0.261)

HR

95%CI

P value

HR

95%CI

P value

Unadjusted

0.414

0.351–0.490

 < 0.001

0.526

0.460–0.601

 < 0.001

MELD score-adjusted

0.542

0.457–0.642

 < 0.001

0.646

0.564–0.740

 < 0.001

MELD-Na score-adjusted

0.505

0.426–0.598

 < 0.001

0.614

0.536–0.703

 < 0.001

CTP score-adjusted

0.455

0.385–0.539

 < 0.001

0.568

0.496–0.650

 < 0.001

Multiple Cox analysis risk factors adjusted

0.602

0.502–0.721

 < 0.001

0.704

0. 609–0.814

 < 0.001

  1. Obtained from Cox proportional hazard regression models (a) 30-day survival: adjusted for age, white blood cell count, glutamic-oxaloacetic transaminase, albumin, total bilirubin, INR, international normalized ratio, serum creatinine, alpha fetal protein, hepatitis B virus (> 156,000 vs. < 156,000), pre-existing chronic liver diseases (cirrhosis vs. chronic hepatitis), hepatorenal syndrome (yes vs. no) and hepatic encephalopathy(grade 3 vs. grade 1–2 vs. none); (b) 90-day survival: adjusted for age, white blood cell count, glutamic-oxaloacetic transaminase, total bilirubin, INR, international normalized ratio, serum creatinine, alpha fetal protein, hepatitis B virus (> 156,000 vs. < 156,000), pre-existing chronic liver diseases (cirrhosis vs. chronic hepatitis), hepatic encephalopathy(grade 3 vs. grade 1–2 vs. none), gastrointestinal bleeding (yes vs. no) and infection (yes vs. no)
  2. ACLF Acute-on-chronic liver failure; CTP Child-Turcotte-Pugh; MELD Model for End-Stage Liver Disease; MELD-Na Model for End-Stage Liver Disease with the addition of the Na level; TSH thyroid-stimulation hormone